TY - JOUR
T1 - Prescription patterns following first-line new generation antidepressants for depression in Japan
T2 - A naturalistic cohort study based on a large claims database
AU - Furukawa, Toshi A.
AU - Onishi, Yoshie
AU - Hinotsu, Shiro
AU - Tajika, Aran
AU - Takeshima, Nozomi
AU - Shinohara, Kiyomi
AU - Ogawa, Yusuke
AU - Hayasaka, Yu
AU - Kawakami, Koji
PY - 2013/9/25
Y1 - 2013/9/25
N2 - Background: Several studies have described real-world prescription patterns of first-line antidepressants for depression but little is known about their fate in terms of duration, intensity and changes. Methods: An inception cohort of new onset non-psychotic depression initiating antidepressant treatment with a new generation antidpressive agent was identified in a large health insurance claims database in Japan between 2009 and 2010. The duration and intensity of first-line antidepressants, the timing and kind of second-line antidepressants and the total duration of antidepressant treatment were examined. Results: We identified 1592 patients. The starting dose and the maximum dose attained with the firstline agent appeared to be largely in line with the guideline recommendations although the latter tended toward the minimum of the recommended range. The continuity of the first-line antidepressant was far below the guideline recommendations, with 28%never returning after the initial prescription and 55%dropping out within 3 months. Of all the first-line antidepressants, 14%were subsequently augmented by another psychotropic agent while 17%were switched to another antidepressant after a median of 3 or 2 months, respectively. The choice of the second-line agents varied extremely widely. The total duration of antidepressant therapy was as short as a median of 4 months, with 68%stopping treatment by 6 months. Limitations: The diagnosis of non-psychotic unipolar depression in the claims database analyses remains approximate. Conclusions: The current guidelines are grossly out of touch with the clinical realities. On the one hand, guidelines need to reflect the real-world practices; on the other hand clinicians should limit their treatment options and allow evidence-based comparative effectiveness research among them so that patients shall no longer be given less effective and more effective treatments without being able to distinguish among them.
AB - Background: Several studies have described real-world prescription patterns of first-line antidepressants for depression but little is known about their fate in terms of duration, intensity and changes. Methods: An inception cohort of new onset non-psychotic depression initiating antidepressant treatment with a new generation antidpressive agent was identified in a large health insurance claims database in Japan between 2009 and 2010. The duration and intensity of first-line antidepressants, the timing and kind of second-line antidepressants and the total duration of antidepressant treatment were examined. Results: We identified 1592 patients. The starting dose and the maximum dose attained with the firstline agent appeared to be largely in line with the guideline recommendations although the latter tended toward the minimum of the recommended range. The continuity of the first-line antidepressant was far below the guideline recommendations, with 28%never returning after the initial prescription and 55%dropping out within 3 months. Of all the first-line antidepressants, 14%were subsequently augmented by another psychotropic agent while 17%were switched to another antidepressant after a median of 3 or 2 months, respectively. The choice of the second-line agents varied extremely widely. The total duration of antidepressant therapy was as short as a median of 4 months, with 68%stopping treatment by 6 months. Limitations: The diagnosis of non-psychotic unipolar depression in the claims database analyses remains approximate. Conclusions: The current guidelines are grossly out of touch with the clinical realities. On the one hand, guidelines need to reflect the real-world practices; on the other hand clinicians should limit their treatment options and allow evidence-based comparative effectiveness research among them so that patients shall no longer be given less effective and more effective treatments without being able to distinguish among them.
KW - Antidepressive agents
KW - Depressive disorder
KW - Drug administration schedule
KW - Patient compliance
UR - http://www.scopus.com/inward/record.url?scp=84888359803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888359803&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2013.05.015
DO - 10.1016/j.jad.2013.05.015
M3 - Article
C2 - 23721923
AN - SCOPUS:84888359803
SN - 0165-0327
VL - 150
SP - 916
EP - 922
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
IS - 3
ER -